What You Should Know:
– Click Therapeutics, a leader in prescription digital therapeutics (DTx), announced today the acquisition of key assets from Better Therapeutics.
– Click’s expansion into cardiometabolic disease follows successful DTx development efforts in other areas, including migraine prevention, depression, schizophrenia, and opioid use disorder.
Strengthening the DTx Pipeline
The acquisition includes several key assets from Better Therapeutics:
- AspyreRx (BT-001): The first FDA-authorized DTx for type 2 diabetes.
- BT-004: A DTx with FDA Breakthrough Device Designation for treating metabolic dysfunction-associated steatohepatitis (MASH).
- BT-002: A DTx designed to reduce blood pressure in patients with hypertension.
- BT-003: A DTx focused on lowering LDL cholesterol in patients with hyperlipidemia.
The strategic acquisition significantly expands Click’s DTx portfolio, complementing their existing offerings in psychiatry, CNS, and pain management. It also strengthens their position in the rapidly growing market for obesity and cardiometabolic disease treatments.
A Personalized Approach to Weight Management
Click’s existing DTx solutions focus on psychiatry, CNS, and pain disorders. By integrating Better Therapeutics’ assets, Click gains immediate traction in the rapidly growing cardiometabolic space, complementing their current offerings.
Click emphasizes the importance of personalized treatment plans for obesity, a complex chronic disease. Their goal is to develop a best-in-class DTx solution that combines:
- Behavioral Therapy: Leveraging Better Therapeutics’ clinically validated approach honed over nine years.
- AI-powered Platform: Click’s platform utilizes advanced engagement techniques and proprietary digital mechanisms to address the disease.
- Medication Integration: The DTx will be optimized to work seamlessly with anti-obesity and diabetes medications like GLP-1s.
Benefits Beyond Weight Management
This acquisition extends beyond obesity. Click plans to leverage Better Therapeutics’ assets to develop DTx solutions for type 2 diabetes, hypertension, hyperlipidemia, and MASH. This holistic approach positions Click as a leader in DTx solutions for a broad range of cardiometabolic conditions.
“There is immense potential in the cardiometabolic space for next-generation ‘smart’ therapeutics that enhance patient care and provider capabilities,” said Rich DeNunzio, Chief Commercial Officer of Click Therapeutics. “The current one-size-fits-all approach to obesity management can be improved with innovative digital therapeutics that tailor treatments to individual needs, leading to improved patient outcomes and the opportunity to create data-driven contracting models with payers. By collaborating with pharma, payers, providers and patients to layer these capabilities onto the latest drugs, we can transform obesity care and enable our partners to succeed in what is soon to be a highly competitive market.”